Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis E Hruby

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Canadian Journal of Microbiology|June 1, 2007
Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmidTravis K Warren, S Amanda Lund, Kevin F Jones, et al.
Expert Review of Anti-Infective Therapy|February 2, 2023
Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potentialAndrew T Russo, Douglas W Grosenbach, Kady M Honeychurch, et al.
Journal of Bacteriology|September 25, 2002
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilinC Hal Jones, Paul Dexter, Amy K Evans, et al.
Virology Journal|March 3, 2006
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteinsJennifer D Yoder, Tsefang S Chen, Cliff R Gagnier, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infectionAklile Berhanu, Jonathan T Prigge, Peter M Silvera, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
In vitro efficacy of ST246 against smallpox and monkeypoxScott K Smith, Victoria A Olson, Kevin L Karem, et al.
Virology Journal|April 30, 2009
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesisYali Chen, Kady M Honeychurch, Guang Yang, et al.
Vaccine|November 2, 2010
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient miceAklile Berhanu, David S King, Stacie Mosier, et al.
Antimicrobial Agents and Chemotherapy|September 16, 2009
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestationAklile Berhanu, David S King, Stacie Mosier, et al.
Antimicrobial Agents and Chemotherapy|April 30, 2014
The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cellsKelsi M Sandoz, William G Valiant, Steven G Eriksen, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Canadian Journal of Microbiology|June 1, 2007
Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmidTravis K Warren, S Amanda Lund, Kevin F Jones, et al.
Expert Review of Anti-Infective Therapy|February 2, 2023
Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potentialAndrew T Russo, Douglas W Grosenbach, Kady M Honeychurch, et al.
Journal of Bacteriology|September 25, 2002
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilinC Hal Jones, Paul Dexter, Amy K Evans, et al.
Virology Journal|March 3, 2006
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteinsJennifer D Yoder, Tsefang S Chen, Cliff R Gagnier, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2015
Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infectionAklile Berhanu, Jonathan T Prigge, Peter M Silvera, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
In vitro efficacy of ST246 against smallpox and monkeypoxScott K Smith, Victoria A Olson, Kevin L Karem, et al.
Virology Journal|April 30, 2009
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesisYali Chen, Kady M Honeychurch, Guang Yang, et al.
Vaccine|November 2, 2010
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient miceAklile Berhanu, David S King, Stacie Mosier, et al.
Antimicrobial Agents and Chemotherapy|September 16, 2009
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestationAklile Berhanu, David S King, Stacie Mosier, et al.
Antimicrobial Agents and Chemotherapy|April 30, 2014
The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cellsKelsi M Sandoz, William G Valiant, Steven G Eriksen, et al.
Pageof 9